Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2013

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Infliximab plus methotrexate

IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.

DRUG

Combination of DMARDs

IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.

DRUG

Methotrexate alone

Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.

Trial Locations (6)

Unknown

Rheumatism Foundation Hospital, Heinola

Hospital for Children and Adolescents, Helsinki

Kuopio University Hospital, Kuopio

Oulu University Central Hospital, Oulu

Tampere University Hospital, Tampere

Turku University Hospital, Turku

All Listed Sponsors
collaborator

Foundation for Paediatric Research, Finland

OTHER

collaborator

Päivikki and Sakari Sohlberg Foundation, Finland

OTHER

collaborator

Rheumatism Foundation Hospital

OTHER

collaborator

Scandinavian Rheumatology Research Foundation

UNKNOWN

collaborator

Paijat-Hame Hospital District

OTHER

lead

Helsinki University Central Hospital

OTHER

NCT01015547 - Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis | Biotech Hunter | Biotech Hunter